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Abstract
Cutaneous leishmaniasis (CL) is an infectious, parasitic disease caused by the protozoan Leishmania. Amphotericin B (AMB) is
a macrolide polyene antibiotic presenting potent antifungal and antileishmanial activity, but due to poor water solubility at
physiological pH, side effects, and toxicity, its therapeutic efficiency is limited. In the present study, poly(lactic-co-glycolic acid)
(PLGA) nanoparticles (NPs) loaded with AMB were generated to reduce drug toxicity and facilitate localized delivery over a
prolonged time. AMB NPs were characterized for particle size, zeta potential, polydispersity index, and degree of aggregation.
In vitro assessments demonstrated its sustained activity against Leishmania major promastigotes and parasite-infected macro-
phages. A single intralesional administration to infected BALB/c mice revealed that AMB NPs were more effective than AMB
deoxycholate in terms of reducing lesion area. Taken together, these findings suggest that AMBNPs improve AMB delivery and
can be used for local treatment of CL.
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Introduction
Leishmaniasis is an infectious disease spread by the bite of
Leishmania-infected female Phlebotomine sandflies while
taking a blood meal [1]. This disease has several clinical
manifestations which are typically categorized as cutaneous
leishmaniasis (CL), the most common form typified by local-
ized skin lesions at the site of infection; mucocutaneous leish-
maniasis which causes extensive destruction of the nasophar-
ynx region and fails to heal without treatment; and visceral
leishmaniasis (VL), the fatal form of the disease where para-
sites reside in the spleen, liver, and bone marrow [2]. After
deposition into the skin, Leishmania are taken up by macro-
phages and other phagocytes where they differentiate into the
intracellular form, the amastigote [3]. Drugs currently admin-
istered to treat CL are constrained by treatment period, route
of administration, suboptimal efficacy, toxicity, and cost [4].
Amphotericin B (AMB) is a macrolide polyene antibiotic
presenting potent antifungal and antileishmanial activity, but
its poor water solubility at physiological pH (< 1 mg/L), high
cost, side effects, and toxicity limit the therapeutic efficiency
and clinical applicability of this drug [5, 6]. AMB exerts its
antileishmanial activity through a high-affinity interaction
with ergosterol, the main membrane component of fungi and
Leishmania [7]. Its binding induces the formation of mem-
brane channels that enhance permeability to ions and small
molecules, leading to parasite death [8]. AMB is active against
both the extracellular promastigote and intracellular
amastigote forms with ED50 values from 0.01 to 0.27 μM
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[9]. The conventional AMB formulation is a micellar suspen-
sion of AMB with sodium deoxycholate (Fungizone®).
However, this formulation may lead to rapid release of the
drug that can induce surfactant-related toxicity [10, 11].
Hence, clinical use of the micellar AMB formulation is asso-
ciated with frequent and severe side effects, including fever,
chills, nausea, vomiting, anemia, and nephrotoxicity, which
often result in treatment failures [12, 13]. Liposomal AMB
(AmBisome®), a lipid-based formulation of AMB, bears a
significantly improved toxicity profile comparedwith conven-
tional amphotericin B deoxycholate [14]. AMB formulations
are used to treat all forms of leishmaniasis, and as such a need
exists for a drug formulation with reduced toxicity, which
delivers the drug to its target as efficiently as possible [6].
Nanoparticles (NPs) are submicron-sized polymeric colloi-
dal particles, which can be applied to entrap, dissolve, bind, or
encapsulate a wide variety of drugs within their polymeric
matrix [15, 16]. Polymeric NPs are generated from either nat-
ural or synthetic polymers [17]. Poly(D,L-lactic-co-glycolic
acid) (PLGA) NPs are extensively used for controlled and
targeted delivery of drugs [18–20] due to their biodegradabil-
ity, biocompatibility, and FDA approval [21, 22]. Moreover,
PLGA polymers exhibit a wide range of degradation rates
depending on their composition and molecular weight [17,
23, 24]. PLGA and modified PLGA NPs [poly(ethylene gly-
col) (PEG), chitosan, and mannose] containing AMB have
been produced and several tested in vitro for activity against
Leishmania [25]. To date, almost all the studies have
employed Leishmania donovani or Leishmania infantum, spe-
cies which cause VL [1]. However, only one report tested
these NPs in animal models demonstrating that parasite spleen
burden was lower in L. donovani-infected hamsters treated
with PLGA-PEG NPs containing AMB (93.2%, 5 mg/kg for
7 days) as compare to animals treated with a similar dose of
the free drug (74.4%) [26].
Currently, the AMB formulations in clinical use for CL are
intravenously administered. Topical administration of AMB is
challenging, owing to its properties and inadequate skin per-
meability [27]. A nano-delivery systemmay be advantageous,
by facilitating direct AMB delivery at the site of infection and
release of the drug in a sustained manner. The purpose of this
study was to design a PLGA-nanoparticulate drug system for
controlled release of AMB that would support intralesional
AMB delivery and antileishmanial activity against
Leishmania major which causes CL.
Materials and methods
Materials
Poly(D,L-lactide-co-glycolide) (PLGA, lactide: glycolide
(50:50) RESOMER® RG 504 H, MW 38,000–54,000),
amphotericin B deoxycholate, and TWEEN® 80 were pur-
chased from Sigma-Aldrich (St Louis, MO, USA).
Amphotericin B (BIA0103) was acquired from Apollo
Scientific (Cheshire, UK). Macrogol 15 hydroxystearate
(Solutol® HS 15) was donated by BASF (Ludwigshafen,
Germany).
Preparation of AMB NPs
AMB-loaded nanoparticles were prepared using a modified
nanoprecipitation method [28]. Briefly, the organic phase,
consisting of 6 mg AMB in 200 μL DMSO and 15 mg
PLGA in 2.5 mL acetone, was added to 5 mL aqueous solu-
tion containing 0.1% w/v Solutol® HS 15. The suspension
was stirred at 900 rpm over 15 min, and then concentrated
by solvent evaporation, followed by centrifugation for 5 min
at 4000 rpm. NPs were washed with water, to remove residual
DMSO, and filtered through a 0.45 μ membrane filter. Blank
NPs were prepared using the same method, but without
adding AMB at any stage of the preparation.
Physicochemical characterization of NPs
Particle size distribution and zeta potential of the NPs were
characterized by dynamic light scattering (DLS) using a
Malvern’s Zetasizer (Nano series, Nanos-ZS, UK). Samples
were prepared in water.
Determination of drug-loading efficiency
AMBNPs were dissolved in 5%DMSO in methanol (v/v) and
the drug concentration was determined using a Genesys-10
UV-Vis spectrophotometer (Thermo Spectronic, Rochester,
USA). AMB was detected at a wavelength of 407 nm.
Morphological evaluation of AMB NPs
Morphological and size evaluation of AMB NPs was carried
out using a high-resolution scanning-electron microscope
(HR-SEM, Carl Zeiss Ultra-Plus). The samples were fixed
on a silicon SEM-stub.
Determination of AMB aggregation state in AMB NPs
AMB (dissolved in DMSO) and AMB NPs were diluted in
PBS (pH 7.4) or methanol, to a final concentration of 4 μg/mL
and 0.1% (v/v) DMSO. The UV-Vis spectra of the solutions
were then recorded from 300 to 450 nm (Genesys-10 UV-Vis
spectrophotometer) at 25 °C. The aggregation ratio was cal-
culated by dividing the maximal absorption of peak I (325–
340 nm) by peak IV (406–409 nm).
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In vitro release kinetics
AMB NPs containing 0.4 mg AMB were placed in dialysis
bags with a molecular cut-off of 12–14 kDa. The dialysis bags
were suspended in 50 mL PBS (containing 1% w/v Tween 80,
pH 7.4) and incubated at 37 °C in an orbital shaking bath
(50 rpm). At predetermined time intervals, 2 mL of the release
medium were discarded and replaced by an equal volume of
fresh medium, in order to maintain sink conditions. After the
2-h sampling time point, the entire volume of medium
(50 mL) was replaced with fresh medium, and the medium
refreshment procedure was resumed. The concentration of
AMB was determined by UV-Vis (Genesys-10 UV-Vis spec-
trophotometer) at a wavelength of 407 nm. The cumulative
percentage of drug released was plotted against time and fitted
into Korsmeyer–Peppas model.
In vitro assessments
Parasite culture
Leishmania major promastigotes MHOM/IL/2010/LRC-
L1412 (P2407) were maintained at 26 °C in RPMI-1640 me-
dium supplemented with 10% fetal calf serum. Intracellular
amastigotes were kept at 37 °C in a 5% CO2 incubator, in
complete RPMI 1640 containing 10% fetal calf serum.
Cytotoxicity assay on THP1 cells
To evaluate the cytotoxic effect of AMB NPs, the human
leukemia monocyte cell line THP1 was used. THP1 cells in
RPMI with 10% fetal calf serum were aliquoted in triplicates
(5.0 × 105 cells/mL; 125 μL per well) into 96-well plates
(Nunc, Roskilde, Denmark). AMB NPs and blank NPs were
then diluted with the same medium (0.01–6.7 μg/mL), added
to the cells, and incubated for 24 h. 2-anilino paullone; a
cytotoxic compound (1 μM) was used as a positive control
as previously described [29]. The AlamarBlue viability indi-
cator (AbD Serotec, Oxford, UK) was added [25 μL (10%)
per well] and plates were incubated for an additional 24 h.
Fluorescence (ex: 544 nm; em: 590 nm) was measured by a
microplate reader (Fluoroskan Ascent FL, Finland). Percent of
THP1 inhibition was then calculated form cell viability plot.
Evaluation of AMB NP antileishmanial activity on L. major
promastigotes
The leishmanicidal activity of AMB NPs on L. major
promastigotes was carried out using the AlamarBlue assay,
as previously described [30]. Briefly, 5 × 106 parasites/mL
(125 μL, L. major promastigotes) were seeded into each well
of 96-well plates (Nunc, Roskilde, Denmark). Serial dilutions
(0.001 to 2.5 μg/mL) of AMB, AMB NPs, and blank NPs
were made in complete promastigote medium containing 1%
DMSO, aliquoted in triplicates (125 μL per well), and incu-
bated for 24 h. The AlamarBlue viability indicator was added
(25 μL per well) and plates were incubated for an additional
24 h. Fluorescence (ex: 544 nm; em: 590 nm) was measured
by a microplate reader (Fluoroskan Ascent FL, Finland).
Complete medium, both with and without DMSO, served as
negative controls (0% inhibition of promastigote growth).
IC50 was determined using serial threefold dilutions of the test
compounds from 0.01 to 20 μg/mL.
Evaluation of AMB NP antileishmanial activity on intracellular
amastigotes
Luciferase-expressing Lm:pSSU-int/LUC promastigotes were
used to infect macrophages, as previously described [31, 32].
The infected THP1 cells (105 cells per well) were treated with
AMB and AMBNPs (0.001–2 μg/mL). Luminescence (intra-
cellular amastigote viability) was measured by a Fluoroskan
microplate reader after adding Steady-Glo® (Promega).
Calculation of the IC50 values and statistical analysis were
carried out using GraphPad Prism Version 6.0b (GraphPad
Software, Inc. San Diego, CA).
In vitro release and sustained antileishmanial activity of AMB
NPs
AMB NPs, AMB, and blank NPs were diluted (20, 2, and
0.2 μg/mL) in RPMI 1640 medium supplemented with
10% FCS. At various time points after diluting the NPs,
1 mL medium was taken and added, in triplicates (125 μL/
well), to 5 × 106 L. major promastigotes per milliliter. After
24 h, 10% Alamar Blue was added and incubated for an
additional 24 h. The fluorescence output, as a result of
AlmarBlue reduction by viable parasites, was read using
a Fluoroskan plate reader (ex: 544 nm, em: 590 nm). The
percent growth inhibition of the L. major promastigotes
was calculated as follows:
Y ¼ k−y
k
 
*100 ð1Þ
where k is the negative control (untreated parasites) and y
is the readings of AMB/AMB NP-treated parasites.
In vivo study
Animal experiments were conducted in accordance with the
Institutional Animal Ethical Committee guidelines which con-
form to the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (Eighth
edition 2011, ethical number: MD-14-13923-3).
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BALB/c mice (5 to 6 weeks old) were subcutaneously in-
oculated with 107 L. major stationary phase promastigotes
(20 μL) at the base of the tail. The lesions were measured once
a week. The lesion size was determined by measuring the
maximal diameter of the outer edges perpendicularly and par-
allel to the dorsal line of the lesion using a mechanical caliper.
Lesion area was calculated as π (length/2 × width/2)2. After
appearance of lesions on day 73, and prior to treatment, the
mice were redistributed among the cages so each group
contained animals with equal-sized lesions. Four treatment
groups (n = 6–7) were established: control—PBS, blank
NPs, 1 mg/kg AMB deoxycholate (intralesional), and
1 mg/kg AMB NPs (intralesional). A single intralesional dose
(100 μL) of each treatment was then administered to the mice
and lesion area determined at subsequent intervals.
Statistical analysis
To determine statistical significance in the in vivo study,
Kruskal-Wallis test and Dunn’s multiple comparisons test
were performed. Differences were considered significant if
P < 0.05.
Results
Characterization of AMB NPs
AMB NPs were prepared using the solvent deposition tech-
nique [33]. A solvent mixture was used to ensure a low mean
particle size of 90 nm, with a satisfactory polydispersity index
(PDI) of 0.27, various aggregation states of AMB [34], and
negative zeta potential value of approximately − 27 mV. SEM
analysis of AMB NPs was in good agreement with results
obtained from DLS (Fig. S1).
The amount of AMB incorporated in PLGA NPs was de-
termined by UV spectroscopy, and the efficiency of AMB
loading was approximately 80%, with a drug content of 24%
(w/w).
Determination of AMB aggregation state in AMB NPs
The peak I to peak IV intensity ratio (I/IV ratio) is a quantita-
tive means of determining the aggregation state of AMB. At
4 μg/mL, AMB dissolved in methanol showed the least ag-
gregation, I/IV ratio (0.37), compared to that of AMB in PBS
(1.5) and AMB NPs (3.0). Moreover, a 20-min incubation at
37 °C led to a decrease in the AMBNP aggregation state (I/IV
ratio = 1.97; Fig. 1a), while at 1 μg/mL the I/IV ratios for
AMB in methanol, AMB NPs, and AMB NPs after 20 min
at 37 °C were 0.34, 1.46, and 0.78, respectively (Fig. 1b).
Additionally, after dilution of AMB NPs, the I/IV ratio was
altered by increased absorbance at 407 nm, accompanied by
decreased absorbance at 327 nm; this ratio decreased further
following a 20-min incubation at 37 °C.
In vitro release of AMB
AMB release from AMB NPs exhibited a biphasic pattern
over a period of 7 days, with an initial burst release accompa-
nied by a sustained release phase (Fig. 2). In the present case,
the data were fitted to the Korsmeyer–Peppas model, resulting
in a release exponent (n) of 0.22 (Fig. S2) indicating Fickian
release, in which drug diffusion is the primary factor in drug
release [35].
Cytotoxicity assay on THP1 cells
The cytotoxicity of blank NPs and AMB NPs was investigat-
ed using the THP1 human macrophage cell line. A negligible
cytotoxic effect of blank NPs and AMB NPs on THP1 cells
was observed up to a concentration of 0.08 μg/mL, demon-
strating their potential as nano-carriers for therapeutic appli-
cations. At 0.2 μg/mL, AMB NPs and blank NPs inhibited
cell viability by 16 and 4%, respectively. At higher concentra-
tions, both blank NPs and AMB NPs were relatively more
toxic (Fig. 3).
In vitro antileishmanial activity of AMB NPs
The antileishmanial activity of free AMB and AMB NPs was
determined 48 h following exposure of L . major
promastigotes and infected macrophages to the loaded parti-
cles. The half maximal inhibitory concentration (IC50) values
on L. major extracellular promastigotes were determined in
three independent experiments and show that there is no sig-
nificant difference in IC50 between AMB and AMB NPs
(0.079 ± 0.004 and 0.083 ± 0.005 μg/mL, respectively). In
comparison, no inhibition was observed using the blank NPs
(Fig. S3).
Viability of luciferase-expressing L. major amastigotes in
infected macrophages was evaluated following treatment with
AMB and AMB NPs. It is important to point out that macro-
phages are the primary host cells for the intracellular stage of
the parasite which is responsible for human and animal dis-
ease. A significant difference was observed (P < 0.01) be-
tween the IC50 of AMB versus AMB NPs (0.071 ± 0.004
and 0.035 ± 0.001 μg/mL, respectively), i.e., AMB NPs were
two times more effective against amastigotes. At a concentra-
tion of 0.2μg/mL, AMBNPs and AMB induced 100 and 90%
inhibition of intracellular parasites, respectively (Fig. S4).
However, at lower concentrations (< 0.1 μg/mL), differences
between the effects of AMB versus AMB NPs on infected
macrophages were more pronounced.
Drug Deliv. and Transl. Res. (2019) 9:76–84 79
In vitro release and sustained antileishmanial activity
of AMB NPs
Prior to determining the in vitro release profile of drug from
AMB NPs, L. major promastigotes were incubated with in-
creasing concentrations of AMB NPs (20, 2, 0.2 μg/mL) for
48 h and the percent growth inhibition assessed. At concen-
trations of 20 and 2 μg/mL, both AMB and AMB NPs
inhibited growth completely, whereas at the lower concentra-
tion (0.2μg/mL), AMB induced 39% growth inhibition, while
the efficacy of AMB NPs remained stable (100% inhibition).
Therefore, a concentration of 0.2 μg/mL AMB NPs was used
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Fig. 1 UV-Vis absorbance
spectral properties of AMB NPs.
a Spectra of AMB (4 μg/mL)
dissolved in PBS or methanol,
AMB NPs, and AMB NPs after
incubation at 37 °C for 20 min. b
Spectra of AMB (1 μg/mL)
dissolved in methanol, AMB
NPs, and AMB NPs after
incubation at 37 °C for 20 min
Fig. 2 In vitro drug release of
AMB from AMB NPs in PBS
with 1% Tween® 80 (pH 7.4,
37 °C) at different time intervals.
Insert shows the drug release
profile over the initial 24 h.
Values are mean ± s.d. of three
experiments
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for the in vitro release experiment. AMB NPs fully inhibited
promastigotes growth over 15 days, indicating slow AMB
release and subsequent long-term exposure (Fig. 4).
Statistical analysis using two-tailed t test revealed that the
differences between AMB and AMB NPs were significant
(P < 0.01) over the time course of the experiment, and proved
the crucial role of AMB encapsulation in enhancing parasite
inhibition for extended time period.
In vivo study
We sought to compare the therapeutic efficacy of intralesional
administration of AMB deoxycholate and AMB NPs. As
depicted in Fig. 5, while no significant difference was noted
between control, blank NPs, and AMB deoxycholate 1 mg/kg,
AMB NPs elicited a significantly greater lesion-reducing ef-
fect as compared to controls (P < 0.01).
Discussion
AMB is a macrolide polyene antibiotic possessing potent an-
tifungal and antileishmanial activity. However, it has several
drawbacks, such as high toxicity and poor water solubility
which limit its efficacy. PLGA NPs loaded with AMB were
produced to minimize AMB toxicity and boost its therapeutic
outcome. AMB NPs were prepared by the nanoprecipitation
approach. While preparation procedure including organic sol-
vents, stabilizers, and surfactants is known to affect the AMB
NPs properties, the conditions utilized in this study produced a
homogeneous population of NPs (size 90 nm, PDI 0.27) with
negative zeta potential value, and high efficiency of AMB
loading (Fig. S1) similar to those described in previous pub-
lications using different solvents, stabilizers, and/or surfac-
tants [25, 36]. The particle size was smaller than that seen
using the emulsion-solvent-evaporation procedure [37, 38].
The toxicity of AMB has been associated with its aggregate
form [39], where the selectivity of AMB between parasitic
and mammalian cells depends on its aggregation state and
the nature of membrane sterol [40]. AMB molecules tend to
remain in their monomeric form in organic solvents such as
methanol, and display four peaks at 346, 362, 382, and
407 nm. These results depicted in Fig. 1 indicate that AMB
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cytotoxicity. The effect of
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PLGA NPs and AMB NPs on the
viability of THP1 cells. 2-Anilino
paullone was used as a positive
control (1 μM) and showed
significant toxicity (0% viability,
data not shown). Percent THP1
viability was calculated using the
AlamarBlue assay. Results are
presented as mean ± SD (n = 3)
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Fig. 4 In vitro release and long-term antileishmanial activity of free AMB
(red), AMB NPs (green), and blank NPs (blue) over time at a concentra-
tion of 0.2 μg/mL AMB. The percent inhibition of L. major
promastigotes was assessed daily using the AlamarBlue assay
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incorporated in PLGA NPs exists in both aggregated and un-
aggregated forms. Furthermore, a hypsochromic shift from
335 to 327 nm was observed for AMB NPs dissolved in
PBS. This shift could be explained by the time- and
concentration-dependent alteration in the aggregation state
of AMB (Fig. 1b), similar to what has been seen in other
studies [36]. Taken together, AMB NPs may act as a reservoir
of AMBmonomers that are primarily released over an extend-
ed time as monomeric AMB species into the aqueous
medium.
AMBNPs were associated with an extended release profile
(Fig. 2). Numerous factors can affect the rate of drug diffu-
sion, including polymer–drug interactions, drug–drug interac-
tions, and water absorption, as well as PLGA degradation
kinetics [41]. As shown in Fig. S2, fitting to Korsmeyer–
Peppas model revealed that drug diffusion is the primary fac-
tor in drug release.
The human THP1 macrophage-like cell line was employed
as they can be used in vitro to examine drug activity against
the intracellular amastigote stage of the parasite, which is re-
sponsible for human disease [42], as well as the toxicity of
NPs [43]. As depicted in Fig. 3, the cytotoxic effect of PLGA
NPs was negligible at therapeutic concentrations of AMB,
similar to a previous report demonstrating that various
PLGA NP formulations had negligible cytotoxicity on
MRC-5 fibroblasts as compared to free AMB or
Fungizone® [36]. Moreover, AMB NPs were more effective
against L. major amastigotes in infected macrophages at low
concentrations. These findings agree with the results depicted
in Fig. 3, which indicate a negligible toxic effect of AMBNPs
on host macrophages in the therapeutic range. The IC50
(0.035 μg/mL) for the AMB NPs on intracellular L. major
amastigotes was half that found for the free drug (0.071 μg/
mL), and similar to IC50’s reported for AMB-loaded PLGA
NPs on intracellular L. infantum amastigotes (D12 = 0.03 μg/
mL, DA12, D24, and DA24 = 0.08, 0.10, and 0.10 μg/mL,
respectively). The lower IC50 of AMB NPs may be the result
of encapsulation in PLGANPs which increases its uptake into
macrophages, similar to reports for bovine serum albumin
[44]. Alternatively, the size of the NPs [45], may be responsi-
ble for the enhanced accumulation of AMBmolecules in mac-
rophages, consequently improving antileishmanial activity.
Interestingly, AMB PLGA NPs prepared by the emulsion-
solvent-evaporation method were also shown to be effective
against L. donovani-infected mouse macrophages (J774.1),
but no significant difference in efficacy between the NPs,
AmBisome, and free drug was demonstrated at the concentra-
tion (1 μM) utilized [38].
The in vitro release experiment for evaluation of sustained
activity of AMB NPs revealed that AMB NPs inhibited
promastigote growth over 15 days (Fig. 4). These results in-
dicate that AMB is released in a controlled manner, achieving
antileishmanial activity for prolonged time. This profile is
expected to minimize drug toxicity associated with exposure
to high drug concentrations caused by rapid release, and to
enhance efficacy. Sustained release of the drug and the pro-
tective role of PLGANPs is important in preventing red blood
cell lysis upon exposure to free AMB and surfactant [46, 47].
Free AMB showed fluctuating effects, which may be due to
degradation of the compound (Fig. 4).
Although AMB deoxycholate (Fungizone®) is effective in
treating visceral leishmaniasis, when administered intrave-
nously, it is ineffective against CL caused by L. major [48,
49]. This study and previous reports demonstrate that PLGA
NPs containing AMB demonstrated a significantly lower tox-
ic effect both in vitro and in animal models when compared to
AMB deoxycholate, and equal of better activity against intra-
cellular amastigotes in vitro [25, 36, 38]. However, studies in
mouse models for leishmaniasis are few, and all involve either
intravenous or intraperitoneal injection of the PLGA NPs [25,
38, 50]. Therefore, we decided to compare the efficacy of
AMB NPs and AMB deoxycholate after single intralesional
injection. This localized method of treatment is frequently
employed in treating human CL with other drugs [51]. AMB
Fig. 5 Antileishmanial activity of
AMB deoxycholate and AMB
NPs in BALB/c mice infected
with L. major. Following lesion
appearance, each group mice
were treated by one intralesional
injection of the respective
compounds. Control mice
received no treatment. Lesion
area = π (length/2 × width/2)2.
Values are means ± s.e.
**P < 0.01
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NPs exhibited significant reduction in the lesion size com-
pared to control, while the remaining groups showed inade-
quate efficacy (Fig. 5). So far, only a few reports of AMB-
loaded PLGA NPs have been reported [25]. Among them, to
the best of our knowledge, there are no reports describing
intralesional injection. In conclusion, these findings suggest
that intralesional AMB-loaded PLGA NPs improve AMB de-
livery and can be used for local treatment of CL, allowing
controlled drug release and circumvention of systemic admin-
istration, as demonstrated in L. major-infected mice.
However, further preclinical and clinical trials are needed to
establish safety and efficacy of this kind of administration.
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